Physician profile
Caleb Taylor
NPI 1508248451
$1,226.11
in general payments reported to CMS, 2019-2025
15 companies · $930 in 2025
The $930 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $296 · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,226.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $265.32 | 2024-2025 | |
| Glaxosmithkline, LLC. | $226.52 | 2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $143.64 | 2024-2025 | Dupixent |
| Erbe USA INC | $125.00 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.53 | 2025 | Glassia, Cuvitru |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.95 | 2025 | Ofev |
| Genzyme Corporation | $60.52 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $56.24 | 2025 | Zerbaxa |
| Amgen INC. | $33.85 | 2025 | Tezspire |
| Philips North America LLC | $29.42 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Ani Pharmaceuticals, INC. | $26.64 | 2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $26.16 | 2025 | Hillrom - Volara System |
| United Therapeutics Corporation | $24.99 | 2025 | Tyvaso |
| Alcresta Therapeutics, INC. | $24.92 | 2025 | Relizorb |
| Insmed, INC. | $14.41 | 2025 | Brinsupri, Arikayce |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.